Leerink Partnrs Has Bearish Outlook for AVDL FY2028 Earnings

Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) – Analysts at Leerink Partnrs decreased their FY2028 earnings per share (EPS) estimates for Avadel Pharmaceuticals in a report issued on Thursday, October 23rd. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings of $1.78 per share for the year, down from their previous estimate of $1.80. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Avadel Pharmaceuticals’ current full-year earnings is ($0.51) per share. Leerink Partnrs also issued estimates for Avadel Pharmaceuticals’ FY2029 earnings at $2.68 EPS.

Avadel Pharmaceuticals (NASDAQ:AVDL) last issued its earnings results on Thursday, August 7th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.08. The company had revenue of $68.13 million for the quarter, compared to the consensus estimate of $60.28 million. Avadel Pharmaceuticals had a negative return on equity of 3.73% and a negative net margin of 1.32%.The firm’s quarterly revenue was up 64.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.14) EPS. Avadel Pharmaceuticals has set its FY 2025 guidance at EPS.

AVDL has been the subject of a number of other research reports. Zacks Research downgraded shares of Avadel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 7th. Needham & Company LLC downgraded shares of Avadel Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Wells Fargo & Company raised shares of Avadel Pharmaceuticals to a “hold” rating in a research note on Wednesday, September 3rd. Piper Sandler lowered Avadel Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Finally, Wall Street Zen lowered Avadel Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Three research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $18.72.

Avadel Pharmaceuticals Price Performance

Shares of AVDL opened at $18.56 on Monday. The company has a market capitalization of $1.80 billion, a price-to-earnings ratio of -618.67 and a beta of 1.46. The business’s 50-day moving average is $15.31 and its 200-day moving average is $11.64. Avadel Pharmaceuticals has a fifty-two week low of $6.38 and a fifty-two week high of $18.65.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Brandes Investment Partners LP increased its holdings in shares of Avadel Pharmaceuticals by 14.5% during the 2nd quarter. Brandes Investment Partners LP now owns 6,487,642 shares of the company’s stock valued at $57,416,000 after acquiring an additional 820,467 shares during the last quarter. Two Seas Capital LP grew its holdings in Avadel Pharmaceuticals by 24.4% during the second quarter. Two Seas Capital LP now owns 6,155,074 shares of the company’s stock valued at $54,472,000 after purchasing an additional 1,208,625 shares during the last quarter. Geode Capital Management LLC grew its holdings in Avadel Pharmaceuticals by 82.3% during the second quarter. Geode Capital Management LLC now owns 2,169,018 shares of the company’s stock valued at $19,198,000 after purchasing an additional 979,422 shares during the last quarter. Kennedy Capital Management LLC grew its holdings in Avadel Pharmaceuticals by 30.1% during the second quarter. Kennedy Capital Management LLC now owns 981,271 shares of the company’s stock valued at $8,684,000 after purchasing an additional 227,228 shares during the last quarter. Finally, Krensavage Asset Management LLC grew its stake in Avadel Pharmaceuticals by 0.9% in the 2nd quarter. Krensavage Asset Management LLC now owns 958,877 shares of the company’s stock valued at $8,486,000 after buying an additional 8,877 shares during the last quarter. Institutional investors and hedge funds own 69.19% of the company’s stock.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.